Today: 1 July 2026
Verizon stock price steady after-hours as report flags consumer chief search; buyback in focus (VZ)
3 February 2026
1 min read

Verizon stock price steady after-hours as report flags consumer chief search; buyback in focus (VZ)

New York, February 2, 2026, 19:19 ET — After-hours

Verizon Communications Inc shares ended Monday up 0.2%, holding steady in late after-hours trading following a report that the carrier is exploring possible replacements for consumer chief Sowmyanarayan Sampath. The stock last changed hands near $44.61.

Verizon shares surged 11.8% on Jan. 30, following its quarterly results and the unveiling of 2026 targets. The buzz comes on the heels of that sharp rerating. Investors have bought into the company’s buyback pledge and an improved profit forecast, stepping away from years of tepid growth.

Verizon hasn’t brought in an executive search firm or started interviewing candidates, according to Light Reading, which cites the Financial Times. The report also notes that Sampath’s departure isn’t certain, and he’s been approached with external job offers.

A Verizon spokesperson refused to comment, calling the report “speculation and rumors.” David Barden of New Street Research warned that ongoing shifts in wireless leadership “is not a positive for the sector” and might hinder Verizon’s plans for 2026. Fierce Telecom

U.S. stocks climbed Monday, with the S&P 500 rising 0.54% and the Dow advancing 1.05%. In the telecom sector, AT&T ticked up 0.34%, but T-Mobile US dropped 1.13%.

Verizon reported adding 616,000 postpaid phone subscribers in the fourth quarter, marking its strongest performance on that front since 2019. The company projects adjusted earnings per share between $4.90 and $4.95 for 2026, excluding certain items, along with free cash flow of at least $21.5 billion. Verizon also confirmed the Jan. 20 closing of its Frontier Communications acquisition, which will broaden its fiber footprint, and revealed an updated MVNO agreement with Charter Communications and Comcast, both of which resell Verizon’s mobile service.

A Jan. 30 SEC filing revealed Verizon’s board has approved a share buyback program capped at $25 billion, with plans to repurchase at least $3 billion in stock during 2026. The company also aims to return roughly $55 billion to shareholders via dividends and buybacks through 2028.

Broker notes are reacting to the shift. On Feb. 2, Wells Fargo analyst Eric Luebchow bumped Verizon’s price target to $44, according to StreetInsider.

Yet, a leadership change in the consumer unit comes amid a strategy that hinges on tighter execution—from pricing strategies to network investments. Should churn rise or promotional costs swell, the stock’s dividend won’t carry the load alone.

Markets kick off again Tuesday, Feb. 3, as investors await a clear signal on the consumer sector and buyback activity. The next key date is April 10, when Verizon stock goes ex-dividend ahead of a $0.7075 payment set for May 1.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • Kymera Therapeutics (KYMR) up 51% YTD as atopic dermatitis drug hits milestones
    July 1, 2026, 2:57 PM EDT. Kymera Therapeutics (KYMR) is up nearly 51% this year, way ahead of the sector's 6.4%. The stock's gain is tied to progress on KT-621, an oral STAT6 degrader for atopic dermatitis and asthma. Kymera wrapped phase IIb enrollment in the BROADEN2 AD trial six months early, aiming to have the pivotal readout by late 2026. Earlier, phase Ib data showed strong STAT6 knockdown and safety. The FDA put KT-621 on Fast Track for moderate-to-severe AD and eosinophilic asthma. Separately, trials for KT-485, in partnership with Sanofi, led to a $20 million milestone, and Kymera is still developing KT-579. Its alliances with Sanofi and Gilead are part of the company's long-term plans.
Nippon India Silver ETF price today: SILVERBEES slides as silver swings shake bullion ETFs
Previous Story

Nippon India Silver ETF price today: SILVERBEES slides as silver swings shake bullion ETFs

Amphenol stock price steadies near $145 after earnings whipsaw as traders eye Tuesday’s U.S. shutdown vote
Next Story

Amphenol stock price steadies near $145 after earnings whipsaw as traders eye Tuesday’s U.S. shutdown vote

Go toTop